Sub-committee to study online pharma sale invites comments

A sub-committee, constituted by the health ministry to examine the issue of online sale of medicines has invited comments from various stakeholders, including public, companies, associations and trade bodies. Leading e-commerce player Snapdeal had launched sale of prescription drugs online early this year.

However, in May, the Maharashtra's Food and Drug Administration (FDA) filed a First Information Report (FIR) against Snapdeal chief executive Kunal Bahl and the company's directors for violation of the Drugs and Cosmetics Act, 1940, and the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

ALSO READ: Maharashtra FDA files FIR against Snapdeal CEO, directors

Comments need to be sent to Harshadeep Kamble, Commissioner at the Food and Drugs Administration by September 28, said a notice from the Office of Drugs Controller General of India (DCGI). Kamble heads the sub-committee constituted by Drugs Consultative Committee, a statutory body under the Drugs and Cosmetics Act of 1940.

The sub-committee has to look into the provisions of the Act, examine the practices being followed in the developed countries, and evaluate the risks and concerns of online sale and its impact on public health.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel